Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 3/20 | 0.55 |
| ▸ | KDM1A | O60341 | 1/20 | 0.54 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088055 | 1.00 | PREP (0.55) | PREPKDM1ARCOR1ACE2SMN1; SMN2 | |
| SCHEMBL3076586 | 1.00 | PREP (0.55) | PREPKDM1ARCOR1ACE2SMN1; SMN2 | |
| SCHEMBL3076590 | 1.00 | PREP (0.55) | PREPKDM1ARCOR1ACE2SMN1; SMN2 | |
| SCHEMBL3088051 | 1.00 | PREP (0.55) | PREPKDM1ARCOR1ACE2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL2505417 | 0.99 | KDM1A (0.56) | PREPKDM1ARCOR1ACE2SMN1; SMN2 | |
| SCHEMBL3011829 | 0.86 | PREP (0.56) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10310512 | 0.86 | PREP (0.56) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL21192894 | 0.85 | CYP2C19 (0.55) | PREPACE2SMN1; SMN2NPSR1CYP2C19 | |
| SCHEMBL12612788 | 0.85 | PREP (0.55) | PREPACE2SMN1; SMN2NPC1RAB9A | |
| SCHEMBL14635896 | 0.85 | PREP (0.55) | PREPACE2SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| CN-101687036-A | CHK1 inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies | ASTRAZENECA AB | 2010-03-31 | — | — | CN | disclosed |
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1869052-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | AstraZeneca AB (SE) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006106326-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | ASTRAZENECA AB (SE) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275570-A1 | SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS | CHEK1, PDK1, CHEK2 | PREP 3747/4885KDM1A 1449/4885RCOR1 1864/4885 |
| US-20100226917-A1 | METHODS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | CHEK1, CHEK2, MCL1 | PREP 3832/4885KDM1A 263/4885RCOR1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.